Labcorp (LH) announced PGDx elio tissue complete has been CE-marked under the European Union’s new In Vitro Diagnostic Regulation, or IVDR. It is now the first and only test of its kind in the EU CE-marked for comprehensive solid tumor profiling. This in vitro diagnostic assay, which has been cleared by the FDA, supports physicians in delivering guideline-based care for patients with solid tumors. With this CE-marking, the test can now be offered by more laboratories across the EU.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp price target raised to $305 from $282 at UBS
- Labcorp price target raised to $310 from $290 at Truist
- Labcorp price target raised to $302 from $290 at Baird
- Labcorp price target raised to $306 from $283 at Morgan Stanley
- Positive Outlook for Labcorp Holdings: Buy Rating Justified by Strong Future Prospects and Strategic Growth Initiatives